Myelodysplastic Syndromes
"Myelodysplastic Syndromes" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Clonal hematopoietic stem cell disorders characterized by dysplasia in one or more hematopoietic cell lineages. They predominantly affect patients over 60, are considered preleukemic conditions, and have high probability of transformation into ACUTE MYELOID LEUKEMIA.
| Descriptor ID |
D009190
|
| MeSH Number(s) |
C15.378.190.625
|
| Concept/Terms |
Myelodysplastic Syndromes- Myelodysplastic Syndromes
- Myelodysplastic Syndrome
- Syndrome, Myelodysplastic
- Syndromes, Myelodysplastic
- Dysmyelopoietic Syndromes
- Dysmyelopoietic Syndrome
- Syndrome, Dysmyelopoietic
- Syndromes, Dysmyelopoietic
Hematopoetic Myelodysplasia- Hematopoetic Myelodysplasia
- Hematopoetic Myelodysplasias
- Myelodysplasia, Hematopoetic
- Myelodysplasias, Hematopoetic
|
Below are MeSH descriptors whose meaning is more general than "Myelodysplastic Syndromes".
Below are MeSH descriptors whose meaning is more specific than "Myelodysplastic Syndromes".
This graph shows the total number of publications written about "Myelodysplastic Syndromes" by people in this website by year, and whether "Myelodysplastic Syndromes" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 3 | 5 | 8 |
| 1995 | 5 | 0 | 5 |
| 1996 | 7 | 2 | 9 |
| 1997 | 5 | 4 | 9 |
| 1998 | 10 | 2 | 12 |
| 1999 | 6 | 0 | 6 |
| 2000 | 11 | 1 | 12 |
| 2001 | 13 | 3 | 16 |
| 2002 | 23 | 9 | 32 |
| 2003 | 18 | 6 | 24 |
| 2004 | 17 | 6 | 23 |
| 2005 | 14 | 3 | 17 |
| 2006 | 23 | 6 | 29 |
| 2007 | 33 | 7 | 40 |
| 2008 | 30 | 2 | 32 |
| 2009 | 28 | 6 | 34 |
| 2010 | 33 | 5 | 38 |
| 2011 | 49 | 1 | 50 |
| 2012 | 26 | 1 | 27 |
| 2013 | 33 | 5 | 38 |
| 2014 | 49 | 4 | 53 |
| 2015 | 40 | 2 | 42 |
| 2016 | 41 | 5 | 46 |
| 2017 | 37 | 6 | 43 |
| 2018 | 46 | 3 | 49 |
| 2019 | 28 | 3 | 31 |
| 2020 | 38 | 1 | 39 |
| 2021 | 40 | 4 | 44 |
| 2022 | 44 | 1 | 45 |
| 2023 | 34 | 1 | 35 |
| 2024 | 30 | 5 | 35 |
To return to the timeline,
click here.
Below are the most recent publications written about "Myelodysplastic Syndromes" by people in Profiles.
-
The IL-1? inhibitor canakinumab in previously treated lower-risk myelodysplastic syndromes: a phase 2 clinical trial. Nat Commun. 2024 Nov 13; 15(1):9840.
-
A Phase 1 First-in-Human Study of the MCL-1 Inhibitor AZD5991 in Patients with Relapsed/Refractory Hematologic Malignancies. Clin Cancer Res. 2024 Nov 01; 30(21):4844-4855.
-
Influence of TP53 gene mutations and their allelic status in myelodysplastic syndromes with isolated 5q deletion. Blood. 2024 10 17; 144(16):1722-1731.
-
Integrated Clinical Genotype-Phenotype Characteristics of STAT3-Mutated Myeloid Neoplasms. Clin Cancer Res. 2024 Oct 15; 30(20):4681-4689.
-
Data-driven, harmonised classification system for myelodysplastic syndromes: a consensus paper from the International Consortium for Myelodysplastic Syndromes. Lancet Haematol. 2024 Nov; 11(11):e862-e872.
-
Update on Recommendations for Surveillance for Children with Predisposition to Hematopoietic Malignancy. Clin Cancer Res. 2024 Oct 01; 30(19):4286-4295.
-
Is luspatercept the new standard of care in transfusion-dependent low-risk myelodysplastic syndromes? Clin Adv Hematol Oncol. 2024 Oct; 22(8):367-369.
-
Glutaminase inhibition in combination with azacytidine in myelodysplastic syndromes: a phase 1b/2 clinical trial and correlative analyses. Nat Cancer. 2024 Oct; 5(10):1515-1533.
-
The immunobiology of myelodysplastic neoplasms: a mini-review. Front Immunol. 2024; 15:1419807.
-
Clonal hematopoiesis: malignant implications, extrahematologic manifestations, and management. Clin Adv Hematol Oncol. 2024 Sep; 22(7):320-327.